Valeant's ($VRX) relationship with now-dissolved specialty pharmacy Philidor may be the one that has drawn the most scrutiny from short sellers, investors and regulators. But it was litigation from another specialty pharmacy, R&O, that opened up the controversy in the first place. Now, Valeant has settled that R&O lawsuit, it said Wednesday--but that hardly means it's out of the woods. As the Canadian drugmaker recently disclosed, the SEC is investigating, and sources have told The Wall Street Journal that its Philidor connections are the subject of the probe. Release | More